ABT · 10-Q · 2026Q2 · Full report

Liquidity and Cash Position

ABBOTT LABORATORIES · 2026-07-28 · Importance 66 · Surprise 74 · From source text

Cash and cash equivalents declined from $8.5 billion at December 31, 2025, to $5.1 billion at June 30, 2026. The $3.4 billion decrease primarily reflected cash funding for the Exact Sciences acquisition, repayment of $2.8 billion of assumed debt, dividends, share repurchases, and capital expenditures. Working capital declined from $9.5 billion to $6.7 billion over the same period, while operating cash flow increased $339 million to $3.8 billion in the first six months. Abbott’s June 30, 2026, long-term debt ratings were A+ from S&P Global Ratings and Aa3 from Moody’s Investors Service.

Key facts

• Working capital was $6.7 billion at June 30, 2026 and $9.5 billion at December 31, 2025.
• Cash and cash equivalents decreased from $8.5 billion at December 31, 2025 to $5.1 billion at June 30, 2026.
• Cash and cash equivalents at June 30, 2026: $5,104 million.
• Cash and cash equivalents at December 31, 2025: $8,522 million.

Impact estimates